SLC5A2 and cancer: Given that different SGLT2 inhibitors may have distinct pharmacodynamic and pharmacokinetic profiles, it is essential to conduct comparative effectiveness studies to better understand the relative safety and efficacy of these agents in cancer patients undergoing various forms of cancer treatment.